New study highlights the value of a whole health approach
managing chronic conditions and supporting members using
GLP-1s
NEW
YORK, Nov. 13, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced new research presented at
the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated
the value of associating physical activity tracking alongside blood
sugar tracking for people living with diabetes and
pre-diabetes.
Dario's digital health solutions help drive healthier behaviors
to improve the management of chronic conditions by combining a
clinically intelligent platform with highly personalized digital
and human coaching. Connected devices capture clinical and
behavioral data into a single platform and billions of consumer
insights can guide highly personalized journeys to measurably
improve health outcomes. Dario's cardiometabolic solution
integrates support for members managing diabetes, blood pressure
and weight, with a special program for those taking a GLP-1, or
anti-obesity medication, collecting clinical measurements along
with activity, diet and medication information to support a whole
health approach.
The new study examined the blood glucose and walking data of 989
Dario users to understand the impact of integrating clinical and
behavioral data in a single digital app-based experience. The
results demonstrated significantly reduced blood glucose levels in
the first four months of using Dario and increased step levels in
the same timeframe maintained for 12 months. In addition, the
results demonstrated clinically significant reductions in blood
glucose levels in users who tracked at least 400 steps per day.
"I believe this new research shows the potential for an
integrated digital solution to help people manage their overall
health. We are excited to share this new data as another example of
how our highly personalized approach to improving behaviors can
help people take control of their overall health and realize better
results," said Yifat Hershcovitz, Ph.D., Vice President of Clinical
and Scientific Affairs at Dario.
"Improving health behaviors is the key to improving outcomes,
and Dario is intensely focused on the intersection of those
behaviors with clinical intelligence gained from more than a decade
of consumer engagement. We are excited to see this new study shed
light on the impact a singular focus on whole health can have for
our members and our partners," said Omar
Manejwala, M.D., Chief Medical Officer of Dario.
The research was conducted in partnership with the Integrative
Pain Laboratory, School of Public Health at the University of Haifa.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Our platform and suite of solutions
deliver personalized and dynamic interventions driven by data
analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Our user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the benefits that may be realized by using the Dario solution.
Without limiting the generality of the foregoing, words such as
"plan," "project," "potential," "seek," "may," "will," "expect,"
"believe," "anticipate," "intend," "could," "estimate" or
"continue" are intended to identify forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario™
as described herein) may differ significantly from those set forth
in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parella
Investor Relations Manager
+315-378-6922
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo -
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/dario-publishes-new-research-demonstrating-that-dario-users-that-increased-physical-activity-can-maintain-reduced-blood-glucose-301986051.html
SOURCE DarioHealth Corp.
